Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Glucagon
The body's own counter-insulin hormone, available as approved injection and nasal rescue products — another proof that 'nasal peptide' is not shorthand for experimental.
Pramlintide
A synthetic amylin analogue approved as an add-on in insulin-treated diabetes.
How far human research has progressed
Glucagon
Long-approved essential rescue medicine, multiple formulationsPramlintide
Approved adjunct medicine with long post-marketing historyClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Glucagon
Not separately assessed; see the full profile.Pramlintide
Not separately assessed; see the full profile.Human research context
Glucagon
Long-approved essential rescue medicine, multiple formulationsPramlintide
Approved adjunct medicine with long post-marketing historyHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Glucagon
Pramlintide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Glucagon
Pramlintide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Glucagon
Pramlintide
Regulatory status (legal position, not proof it works)
Glucagon
Named regulators: FDA (US)
Approved in multiple formulations — injectable glucagon kits and prefilled products, and a dry nasal powder (Baqsimi) — for the treatment of severe hypoglycaemia in people with diabetes. Indications and age ranges differ by product label.
Pramlintide
Named regulators: FDA (US)
FDA-approved (Symlin) as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin and have not achieved adequate control. Approval is specific to that adjunctive role.
Common claims
Glucagon
- · Rapidly reverses severe hypoglycaemia when the person cannot take oral carbohydrates
Pramlintide
- · Improves post-meal glucose control as an insulin adjunct
- · Modest weight effects in studied populations
How settled our evidence rating is
Glucagon
Pramlintide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Glucagon
No established human cancer signal; glucagonoma-related physiology is a separate disease context.Pramlintide
No established human cancer signal within approved use.What this adds up to, in plain English
Glucagon
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Pramlintide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation